GSK-3 inhibitor 4
Based on 1 Customer Validation
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of GSK-3, CDK2, and CDK5, with IC50 values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.02%
- CAS. Nr.: 2227279-83-4
- Formel: C22H15F2N5O
- Molecular Weight:403.38
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
|
GSK-3α 0.45 nM (IC50) |
GSK-3β 0.56 nM (IC50) |
CDK2 0.47 μM (IC50) |
CDK5 0.68 μM (IC50) |
GSK-3 inhibitor 4 (compound 40) exhibits excellent selectivity against CDK2 (840-fold, IC50 = 0.47 μM), CDK5 (1200-fold, IC50 = 0.68 μM), GSK-3β (IC50 = 0.56 nM), and GSK-3α (IC50 = 0.45 nM)[1].
GSK-3 inhibitor 4 has good permeability and exhibits a high ability to bind to plasma proteins and brain tissue due to its lipophilic nature[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
GSK-3 inhibitor 4 (2 mg/kg, i.v.; 10 mg/kg, p.o.) exhibite low-moderate clearance ranging from 15.8 to 23.3 mL/min/kg and are well-absorbed when administered orally as a solution[1].
Pharmacokinetic Parameters of GSK-3 Inhibitor 4 (compound 40) in Mice[1]
| IV PK parameters | oral PK parameters | |||||
| CL (mL min-1 kg-1) | Vdss (L/kg) | MRT (h) | t1/2 (h) | AUCtot (μM h) | Cmax (μM) | F% |
| 18.9 | 2.6 | 2.3 | 2.8 | 11.7 | 1.5 | 53 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:3xTg mice were bred onto the C57BL6 background and bred as homozygotes. Male animals between the ages of five to seven months were used for the study[1].
-
Dosage:10 mg/kg
-
Administration:Oral gavage (p.o.)
-
Result:Produced a 37% reduction in pTau396, when administered orally as a nanosuspension at a dose of 10 mg/kg.
-
Animal Model:male C57BL6 mice (Pharmacokinetic assay)[1]
-
Dosage:2 mg/kg, 10 mg/kg.
-
Administration:Kept for 8 h fasting prior to formulation administration. intravenous and oral routes of administration to mice at a dose of 2 and 10 mg/kg, respectively.
-
Result:Exhibited clearance ranging from 15.8 to 23.3 mL /min/kg , halflives ranging from 2.5 to 2.9 h and were readily orally bioavailable (F% = 53).
Chemical Information
-
CAS. Nr. 2227279-83-4
-
Appearance Solid
-
Molecular Weight 403.38
-
Formel C22H15F2N5O
-
Color Light yellow to yellow
-
SMILES
O=C(C1=NC(NC2=CC=C(C=C2)F)=NC=C1)NC3=C(C4=CC=C(F)C=C4)C=CN=C3
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Reinheit & Dokumentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
GSK-3 inhibitor 4 Related Classifications
HY-154852 Related Classifications
Powered by Bioz